This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ünalp, A. Articles by Öztürk, A. Search for Related Content PubMed PubMed Citation Articles by Ünalp, A. Articles by Öztürk, A. Social Bookmarking                         What's this?

Comparison of the Effectiveness of Topiramate and Sodium Valproate in Pediatric Migraine

Department of Pediatrics, Division of Pediatric Neurology, Behcet Uz Child Disease and Pediatric Surgery Training and Research Hospital, Izmir, Turkey, aycanunalp{at}mynet.com

Nedret Uran, MD

Department of Pediatrics, Division of Pediatric Neurology, Behcet Uz Child Disease and Pediatric Surgery Training and Research Hospital, Izmir, Turkey

Aysel Öztürk, MD

Department of Pediatrics, Division of Pediatric Neurology, Behcet Uz Child Disease and Pediatric Surgery Training and Research Hospital, Izmir, Turkey

Frequent migraine headaches can have a significant impact on disability, prompting the need for early recognition and treatment. The objective of this study is to compare the efficacy of topiramate and sodium valproate for the prevention of pediatric migraine, retrospectively. Mean monthly migraine frequency, intensity, and duration in the 28 patients treated with topiramate decreased from 15.3 ± 10.1 to 4.4 ± 5.5 episode, from 6.8 ± 1 to 3.2 ± 1, and from 10.2 ± 9.4 to 2.4 ± 3.1 hours, respectively. Headache disability improved with a reduction of Pediatric Migraine Disability Assessment score from 36 ± 29.5 to 4.6 ± 6.5 (P < .05). Similarly, mean monthly headache frequency, headache intensity, headache duration, and Pediatric Migraine Disability Assessment score in the 20 patients treated with sodium valproate decreased from 20.1 ± 10.2 to 6.6 ± 8.6, from 7.1 ± 1 to 3.4 ± 2.1, from 7 ± 12 to 1.4 ± 2.5 hours, and from 20.5 ± 16.1 to 5.5 ± 9.2, respectively (P < .05). In conclusion, valproate and topiramate seem to be able to manage successfully childhood migraine without substantial differences in efficacy.

Key Words: topiramate • sodium valproate • migraine • Pediatric Migraine Disability Assessment

Journal of Child Neurology, Vol. 23, No. 12, 1377-1381 (2008)
DOI: 10.1177/0883073808318547


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?